Buy Krystal BiotechShort Term Trading Advice by Naranj Capital
Buy Krystal Biotech
● Buy Range- 185 - 188
● Target- 200 - 203
● StopLoss- 180
● Potential Return- 6-8%
● Duration- 12-14 Trading Days
1KRYS trade ideas
$KRYS getting ready to march back up...This one is ready, hit $100 on solid news, dropped after funding round, now ready to start a march back up towards the $90's...
$KRYS great day today...Solid move on really good data, this company has a bright future, now to see if they do an offering.
KRYS, RSI Indicator left the overbought zone on January 07, 2021This is a signal that KRYS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked back and found 25 similar cases where KRYS's RSI Indicator left the overbought zone, and in 20 of them led to a successful outcome. Odds of Success: 80%. Current price $64.14 is above $59.65 the highest support line found by Tickeron A.I. Throughout the month of 12/04/20 - 01/07/21, the price experienced a +15% Uptrend. During the week of 12/30/20 - 01/07/21, the stock enjoyed a +8% Uptrend growth.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Indicator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further, Tickeron A.I. detected that in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
KRYS broke above its upper Bollinger Band on January 06, 2021. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Krystal Biotech - good entryThese are my thoughts on KRYS. They are meant to give you an idea, not trading advice.
This chart comes together like lego. Just don't step on it. Target around 80$. Could take a few months.
Dips below 40$ are my buying opportunities. Not saying it can't go lower.
Please be careful, as the market never gives you certainties, only probabilities!
ALWAYS REMEMBER THIS WHEN YOU TRADE
Krystal Biotech Announces Positive Interim Results from Phase 1/KRYS: Krystal Biotech, Inc.
2020-05-14 08:00:10
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)
Extended Parabola #VolatilitywatchKRYS has hit FIB golden ratio resistance and peaked out on 5th wave. Looking for pullback to low $40's then we'll find out if it wants to fill the gap.
Please like/ comment so I can continue looking for awesome trades. Thank you in advance.
Message me if your interested in learning more on pattern analysis . Follow trend, Buy low sell high!!
Follow me on Instagram or Twitter @VolatilityWatch
Disclosure: I am not a financial advisor. This is not a note to buy or sell. Please do your homework before investing
KRYS with its High Volume June 25, 2019KRYS broke its mid and long term resistance yesterday with high volume. There is a probability the price would test its' new support at $39 area before continuing its' move upward.
Krystal Biotech Announces Positive Results from Phase 2 ClinicalKRYS: Krystal Biotech, Inc.
2019-06-24 08:00:00
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103 - GlobeNewswire
KRYS Receives Rare Pediatric Disease Designation from the FDAKRYS: Krystal Biotech, Inc.
2018-08-23 08:00:00
Krystal Biotechs’ KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis
Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FKRYS: Krystal Biotech
2018-08-09 08:00:00
Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis
